Ankündigung • Jan 23
Synlogic, Inc.(OTCPK:SYBX) dropped from S&P TMI Index Synlogic, Inc.(OTCPK:SYBX) dropped from S&P TMI Index Ankündigung • Jan 22
Synlogic, Inc.(OTCPK:SYBX) dropped from NASDAQ Composite Index Synlogic, Inc. has been dropped from the NASDAQ Composite Index . New Risk • Jan 21
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$6.55m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Revenue is less than US$1m. Market cap is less than US$10m (US$6.55m market cap). Ankündigung • Nov 27
Synlogic, Inc. Receives Notice of Nasdaq Delisting Due to Public Shell Status and Operational Decline On November 21, 2025, Synlogic, Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC that stated the Staff’s belief that the Company is a “public shell” and that, therefore, the continued listing of its securities is no longer warranted in the view of the Staff. In the Notice, the Staff explained that it based this belief on its review of the Company’s public disclosures and materials submitted to the Staff by the company. In addition, the Staff noted its belief is supported by the Company’s lack of revenue generating assets and the substantial reduction in employees and operations since February 2024. The Staff also considered the company’s quarterly reports on Forms 10-Q filed on May 8, 2025, August 7, 2025, and November 13, 2025, respectively, which indicated that the Company has not generated any revenue for the nine months ended 2025 and that the company had research and development expenses of only $16,000. The Notice further advised that, unless the Company timely requests a hearing before a Hearings Panel, it would be subject to suspension/delisting. The company disagrees with the Staff’s view regarding the Company’s status as a “public shell” and, accordingly, intends to timely request a hearing. The hearing request will automatically stay any suspension or delisting action pending the hearing and the expiration of any additional extension period that may be granted by the Panel following the hearing. However, there can be no assurance that the Company’s hearing will be successful, or that, if successful, the Company will be able to maintain compliance with all applicable listing criteria. Ankündigung • Nov 14
Synlogic, Inc., Annual General Meeting, Dec 15, 2025 Synlogic, Inc., Annual General Meeting, Dec 15, 2025. Valuation Update With 7 Day Price Move • Jul 31
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to US$1.51, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 19x in the Biotechs industry in Europe. Total loss to shareholders of 91% over the past three years. Valuation Update With 7 Day Price Move • Jul 15
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to US$1.52, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 18x in the Biotechs industry in Europe. Total loss to shareholders of 91% over the past three years. Reported Earnings • Mar 08
Full year 2024 earnings released: US$1.92 loss per share (vs US$8.81 loss in FY 2023) Full year 2024 results: US$1.92 loss per share (improved from US$8.81 loss in FY 2023). Net loss: US$23.4m (loss narrowed 59% from FY 2023). Revenue is expected to decline by 150% p.a. on average during the next 2 years, while revenues in the Biotechs industry in the United Kingdom are expected to grow by 12%. Ankündigung • Feb 22
Synlogic, Inc. Announces Resignation of Michael Heffernan as A Member of the Board of Directors and as A Member of the Audit Committee and Nominating and Governance Committee Synlogic, Inc. announced the resignation of Michael Heffernan as a member of the board of directors and as a member of the audit committee and nominating and governance committee of the Board, effective immediately. Reported Earnings • Nov 14
Third quarter 2024 earnings released: US$0.01 loss per share (vs US$2.57 loss in 3Q 2023) Third quarter 2024 results: US$0.01 loss per share (improved from US$2.57 loss in 3Q 2023). Net loss: US$117.0k (loss narrowed 99% from 3Q 2023). Revenue is expected to decline by 118% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the United Kingdom are expected to grow by 20%. Ankündigung • Nov 07
Synlogic, Inc., Annual General Meeting, Dec 04, 2024 Synlogic, Inc., Annual General Meeting, Dec 04, 2024. New Risk • Sep 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$49m free cash flow). Share price has been highly volatile over the past 3 months (9.3% average weekly change). Shareholders have been substantially diluted in the past year (156% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$4.4m net loss in 2 years). Revenue is less than US$5m (US$3.2m revenue). Market cap is less than US$100m (US$17.3m market cap). New Risk • Aug 13
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$49m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$49m free cash flow). Shareholders have been substantially diluted in the past year (156% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$4.4m net loss in 2 years). Share price has been volatile over the past 3 months (9.3% average weekly change). Revenue is less than US$5m (US$3.2m revenue). Market cap is less than US$100m (US$16.4m market cap). Reported Earnings • Aug 09
Second quarter 2024 earnings released: EPS: US$0.17 (vs US$3.21 loss in 2Q 2023) Second quarter 2024 results: EPS: US$0.17 (up from US$3.21 loss in 2Q 2023). Net income: US$2.01m (up US$17.1m from 2Q 2023). Revenue is expected to decline by 200% p.a. on average during the next 2 years, while revenues in the Biotechs industry in the United Kingdom are expected to grow by 17%. New Risk • Jun 12
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$46m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$46m free cash flow). Shares are highly illiquid. Shareholders have been substantially diluted in the past year (157% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$36m net loss next year). Revenue is less than US$5m (US$3.2m revenue). Market cap is less than US$100m (US$19.0m market cap). Reported Earnings • May 15
First quarter 2024 earnings released: US$2.60 loss per share (vs US$3.39 loss in 1Q 2023) First quarter 2024 results: US$2.60 loss per share. Revenue: US$8.0k (down 95% from 1Q 2023). Net loss: US$31.6m (loss widened 102% from 1Q 2023). Revenue is expected to decline by 188% p.a. on average during the next 2 years, while revenues in the Biotechs industry in the United Kingdom are expected to grow by 20%. Ankündigung • Feb 18
Cable Car Capital Discloses its Views on Synlogic On February 16, 2024, Cable Car Capital LLC announced that it wishes to express condolences on the recent disappointing clinical outcome while commending Synlogic, Inc.’s Board of Directors on its swift response. Cable Car Capital stated that it intends to provide input into the announced strategic alternatives review process. Ankündigung • Feb 03
Synlogic, Inc. Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria Synlogic, Inc. announced the publication of a manuscript detailing the development and activity of SYNB1353 in preclinical models and demonstrating safety, tolerability, and clinical proof of mechanism in healthy volunteers through the successful lowering of methionine (Met), a precursor to homocysteine, in a dietary model of classical homocystinuria (HCU). Among findings outlined in the manuscript, SYNB1353 efficiently degraded both dietary and entero-recirculating methionine to prevent its absorption and subsequent conversion to homocysteine in preclinical models, suggesting that SYNB1353 should result in lowering of plasma homocysteine levels in HCU patients. In addition, in results from the clinical study in healthy volunteers, SYNB1353 was generally well-tolerated and adverse events were mild to moderate, transient, and predominantly gastrointestinal in nature. The proportion of subjects reporting gastrointestinal events were similar for the SYNB1353 and placebo cohorts (36.4% and 37.5%, respectively). Ankündigung • Nov 18
Synlogic, Inc. Appoints Chief Financial Officer Changes, Effective December 1, 2023 Synlogic, Inc. announced the appointment of Michael Jensen, Chief Financial Officer of Synlogic, Inc. (the “Company”) resigned from his role as Chief Financial Officer of the Company, effective December 1, 2023 (the “Departure Date”). Mr. Jensen’s departure is not the result of any disagreement with the Company on any matter related to the Company's operations, policies or procedures. In connection with Mr. Jensen’s resignation, on November 13, 2023, Mr. Jensen and the Company entered into a voluntary separation agreement and release of claims (the “Separation Agreement”). Pursuant to the terms of the Separation Agreement, Mr. Jensen will resign as an officer and employee of the Company effective at the close of business on December 1, 2023. Mr. Jensen will assist the Company through the Departure Date in the transition of work in connection with his duties as Chief Financial Officer of the Company. In consideration for, among other things, his compliance with certain restrictive covenants, including customary non-compete and non-solicitation covenants, and a typical release of claims, Mr. Jensen shall receive a lump-sum payment equal to $149,178 in lieu of any other bonus that Mr. Jensen would be eligible for the fiscal year ending December 31, 2023. Mr. Jensen is also entitled to continued health insurance coverage for up to six months following the Departure Date. The foregoing description of the material terms of the Separation Agreement is qualified in its entirety by the full text of the Separation Agreement, a copy of which will be filed as an exhibit to the Company’s annual report on Form 10-K for the year ending December 31, 2023. Reported Earnings • Nov 11
Third quarter 2023 earnings released: US$2.57 loss per share (vs US$3.73 loss in 3Q 2022) Third quarter 2023 results: US$2.57 loss per share (improved from US$3.73 loss in 3Q 2022). Net loss: US$12.1m (loss narrowed 33% from 3Q 2022). Revenue is forecast to grow 75% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in the United Kingdom. Ankündigung • Jun 07
Synlogic, Inc. Announces Implementation of Reduction in Workforce On June 5, 2023, Synlogic, Inc. announced that it is implementing a reduction in workforce designed to focus resources on advancing the Company’s clinical stage programs and research activities that support the current clinical pipeline and its ongoing collaboration with Roche. The realignment is estimated to reduce the Company’s workforce by approximately 21%. The Company expects to complete substantially all of the reduction in workforce by the end of the fiscal quarter ending June 30, 2023. The Company estimates that it will incur approximately $0.9 million of costs in connection with the reduction in workforce related to severance pay and other related termination benefits. The Company communicated the workforce reduction on May 31, 2023 and expects the majority of the costs associated with the strategic realignment to be incurred during the second quarter ending June 30, 2023 and the third quarter ending September 30, 2023. The charges the Company expects to incur in connection with this reduction in workforce are subject to a number of assumptions, risks and uncertainties, and actual results may materially differ. The Company may also incur other material charges not currently contemplated due to events that may occur as a result of, or associated with, these actions. Ankündigung • Jun 06
Synlogic, Inc. Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria Synlogic, Inc. announced the initiation of Synpheny-3, a global, pivotal Phase 3 study evaluating the efficacy and safety of SYNB1934 as a potential treatment for phenylketonuria (PKU). Synpheny-3 is a randomized, placebo-controlled, global, multi-center, pivotal Phase 3 clinical trial designed to evaluate the efficacy and safety of SYNB1934 as a treatment for PKU. The final trial design incorporates feedback from global regulatory agencies including the U.S. Food and Drug Administration (FDA). The global study will enroll approximately 150 patients with plasma phenylalanine (Phe) levels at baseline of >360 µM. Synpheny-3 will include patients ages 18 years and older; an initial subset of data from patients in Part 1 will be used to assess the opportunity to lower the age of enrollment to 12 years of age. Study participants may follow their usual diet while participating in the trial. Synpheny-3 is expected to be conducted at approximately 30 clinical sites across the United States, Canada, Germany, Denmark, Israel, Turkey and Georgia. The study has been designed for patient convenience, and offers opportunities to participate in person, or in a virtual or hybrid format. The study consists of three parts: Part 1 is a run-in period, enabling individualized titration across three potential dose levels (3x1011, 6x1011 and 1x1012), with patients spending a minimum of three weeks at each dose. Part 2 of the trial is a four-week, placebo-controlled, randomized withdrawal that will be used to assess the primary endpoint: change in levels of plasma Phe, with a primary analysis conducted among responders from Part 1. The definition for responders is a reduction in plasma Phe from baseline of >20%. Part 3 is an open-label extension that may extend for up to three years. Ankündigung • Jan 20
Synlogic, Inc. Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria Synlogic, Inc. announced that SYNB1934 was granted Rare Pediatric Disease Designation (RPDD) by the U.S. Food and Drug Administration (FDA) for the potential treatment of phenylketonuria (PKU). Synlogic also received RPDD for SYNB1353 for the potential treatment of homocystinuria (HCU) in December 2022. The FDA grants RPDD for serious and life-threatening diseases that primarily affect individuals from birth to 18 years old and fewer than 200,000 persons in the U.S. RPDD means that the sponsor may be entitled to receive a pediatric priority review voucher (pPRV) if the drug is initially approved for that rare childhood disease. Ankündigung • Jan 04
Synlogic, Inc. Appoints Dave Hava as Head of Research and Development Synlogic, Inc. announced the appointment of Dr. Dave Hava to Head of Research and Development effective January 1, 2023. Through the integration of the company's research and development teams, Dr. Hava will oversee the advancement of clinical stage programs in addition to progressing their collaboration with Roche and select preclinical programs. Since joining Synlogic in 2020, Dr. Hava has served as Chief Scientific Officer and led the research department with responsibilities including the advancement of SYNB1353 into clinical development as a potential treatment of homocystinuria (HCU) and SYNB2081 into IND-enabling studies as a potential treatment for gout; the oversight of research collaborations with Ginkgo Bioworks and Roche; and leadership of Synlogic's preclinical activities in immunology. Dr. Hava joined Synlogic with 16 years of experience in the pharmaceutical industry leading platform and drug development programs, with roles including Chief Scientific Officer at Metera Pharmaceuticals and Pulmatrix Inc., where he led research, development, and clinical teams. Board Change • Oct 13
High number of new directors Independent Director Lisa Kelly-Croswell was the last director to join the board, commencing their role in 2021. Board Change • Jul 27
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Lisa Kelly-Croswell was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Executive Departure • Jun 15
Independent Director Chau Khuong has left the company On the 10th of June, Chau Khuong's tenure as Independent Director ended after 3.8 years in the role. We don't have any record of a personal shareholding under Chau's name. Chau is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.42 years, which is considered inexperienced in the Simply Wall St Risk Model.